A group of federal counselors will soon battle with the decision to approve the first pill devised to do for females what Viagra did for men: improve their sex lives.

A German pharmaceutical major wants to retail a drug with an unsexy trade name "flibanserin" that has revealed competence in igniting a woman's libido by swindling with her brain chemicals.

Even before the FDA's Reproductive Health Drugs Advisory Committee assembles on June 18 to mull over the request, the probability of the drug's endorsement has prompted discussion regarding the medication, whether it will like others in the lineup, signify a long-wanted move toward justice for women's health or the latest example of the pharmaceutical industry producing a dubious chaos to retail redundant and potentially hazardous medicines.

Amy Allina of the National Women's Health Network, a Washington-based advocacy group said, "Achieving a happy and healthy sex life can be a real and important problem for some women".

But, Amy added that they have many queries regarding the 'pink Viagra'.

Viagra's shoot to best-selling status after its 1998 endorsement started out an outbreak of curiosity in me-too drug for women.

Drug manufacturer, Pfizer's expects that its "little blue pill" would also spark women sexual desire, though, making it apparent that a woman's sexuality is more complex than a man's.

Germany's Boehringer Ingelheim is confident that flibanserin is on the threshold of turning out to be the first prescription drug to beat what some have calculated might be a $2 billion market just in the United States.